- Home
- EPOW vs SABS Comparison
EPOW vs SABS Comparison
Compare EPOW & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPOW
- SABS
- Stock Information
- Founded
- EPOW 2014
- SABS 2014
- Country
- EPOW China
- SABS United States
- Employees
- EPOW N/A
- SABS N/A
- Industry
- EPOW Business Services
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- EPOW Consumer Discretionary
- SABS Health Care
- Exchange
- EPOW Nasdaq
- SABS Nasdaq
- Market Cap
- EPOW 23.9M
- SABS 23.9M
- IPO Year
- EPOW 2021
- SABS N/A
- Fundamental
- Price
- EPOW $0.85
- SABS $3.04
- Analyst Decision
- EPOW
- SABS Strong Buy
- Analyst Count
- EPOW 0
- SABS 5
- Target Price
- EPOW N/A
- SABS $12.40
- AVG Volume (30 Days)
- EPOW 17.5K
- SABS 83.2K
- Earning Date
- EPOW 11-29-2024
- SABS 11-06-2024
- Dividend Yield
- EPOW N/A
- SABS N/A
- EPS Growth
- EPOW N/A
- SABS N/A
- EPS
- EPOW N/A
- SABS N/A
- Revenue
- EPOW $45,050,405.00
- SABS $1,512,723.00
- Revenue This Year
- EPOW N/A
- SABS N/A
- Revenue Next Year
- EPOW N/A
- SABS N/A
- P/E Ratio
- EPOW N/A
- SABS N/A
- Revenue Growth
- EPOW 18.16
- SABS N/A
- 52 Week Low
- EPOW $0.53
- SABS $2.16
- 52 Week High
- EPOW $1.36
- SABS $9.72
- Technical
- Relative Strength Index (RSI)
- EPOW 37.72
- SABS 47.24
- Support Level
- EPOW $0.86
- SABS $3.17
- Resistance Level
- EPOW $0.92
- SABS $3.74
- Average True Range (ATR)
- EPOW 0.07
- SABS 0.45
- MACD
- EPOW -0.01
- SABS -0.08
- Stochastic Oscillator
- EPOW 0.05
- SABS 6.34
About EPOW Sunrise New Energy Co. Ltd
Sunrise New Energy Co Ltd is engaged in the manufacturing and sale of graphite anode material for EVs and other lithium-ion batteries. The Company's joint venture is into the construction of a manufacturing plant in Guizhou Province. The plant runs on inexpensive electricity from renewable sources that enables the group to be a low-cost and low environmental impact producer of graphite anode material, Its products include GS-1, GS-2, GS-3, GZD-1, GLD-1, and GZ-1.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.